全文获取类型
收费全文 | 1177篇 |
免费 | 52篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 61篇 |
妇产科学 | 64篇 |
基础医学 | 123篇 |
口腔科学 | 17篇 |
临床医学 | 93篇 |
内科学 | 271篇 |
皮肤病学 | 2篇 |
神经病学 | 44篇 |
特种医学 | 361篇 |
外科学 | 68篇 |
综合类 | 17篇 |
预防医学 | 30篇 |
眼科学 | 3篇 |
药学 | 45篇 |
中国医学 | 1篇 |
肿瘤学 | 49篇 |
出版年
2022年 | 5篇 |
2021年 | 19篇 |
2020年 | 10篇 |
2019年 | 8篇 |
2018年 | 9篇 |
2017年 | 5篇 |
2016年 | 9篇 |
2015年 | 15篇 |
2014年 | 20篇 |
2013年 | 18篇 |
2012年 | 27篇 |
2011年 | 23篇 |
2010年 | 20篇 |
2009年 | 27篇 |
2008年 | 27篇 |
2007年 | 44篇 |
2006年 | 23篇 |
2005年 | 21篇 |
2004年 | 20篇 |
2003年 | 17篇 |
2002年 | 17篇 |
2001年 | 16篇 |
2000年 | 14篇 |
1999年 | 28篇 |
1998年 | 49篇 |
1997年 | 45篇 |
1996年 | 60篇 |
1995年 | 45篇 |
1994年 | 36篇 |
1993年 | 42篇 |
1992年 | 30篇 |
1991年 | 15篇 |
1990年 | 18篇 |
1989年 | 43篇 |
1988年 | 42篇 |
1987年 | 41篇 |
1986年 | 34篇 |
1985年 | 46篇 |
1984年 | 33篇 |
1983年 | 29篇 |
1982年 | 30篇 |
1981年 | 28篇 |
1980年 | 15篇 |
1979年 | 4篇 |
1978年 | 10篇 |
1977年 | 34篇 |
1976年 | 29篇 |
1975年 | 18篇 |
1974年 | 8篇 |
1967年 | 5篇 |
排序方式: 共有1251条查询结果,搜索用时 15 毫秒
51.
Hadar Zigdon DMD Dina Lewinson PhD Tova Bick PhD Eli E. Machtei DMD 《Clinical implant dentistry and related research》2014,16(1):138-144
Purpose: To compare the regenerative potential for vertical bone augmentation of various osteoconductive scaffolds when used in conjunction with barrier domes. Materials and Methods: Following exposure and perforation of the calvarium, a gold occlusive dome was filled with the tested scaffold and anchored by fixation screws. Flaps were repositioned and secured. The four treatment groups, three to five rats each, were as follows: Bio‐Oss collagen (BOC), β‐tricalcium phosphate (TCP), collagen sponge (COL), and empty domes (C). Rats were sacrificed 8 weeks later, and specimens were prepared for histological and histomorphometric analysis. Vertical bone height and total tissue height were measured. Results: The newly regenerated bone appeared mature, highly vascularized, and with no signs of inflammation. Vertical bone height in the TCP group (mean 2.04 ± 0.2 mm) was greater than all other groups (0.76 ± 0.02, 1.52 ± 0.18, and 1.77 ± 0.61 mm for the BOC, C, and COL, respectively) but significantly only for the BOC group (p = .0145). Total tissue height was significantly higher (p < .0001) in both BOC and TCP groups (4.48 ± 0.23 and 5.5 ± 0.24 mm, respectively) compared with COL (3.22 ± 0.11 mm) and C (2.39 ± 0.3 mm) groups. Conclusion: TCP in conjunction with barrier dome resulted in greater vertical bone augmentation in the calvarium of rats. 相似文献
52.
53.
54.
55.
鸟氨酸脱羧酶的生理病理特点及其药物研究概况 总被引:2,自引:0,他引:2
鸟氨酸脱羧酶(ornithinedecarboxylase,ODC)是多胺代谢中的关键酶,广泛存在于人体和动物各组织细胞内,其中对肠细胞的增生、移行和分化起重要作用.机体调节因素比较复杂.在黏膜损伤性疾病及某些癌前病变等细胞大量增生的病理情况下ODC的表达发生改变,可以作为这些疾病分期、预后及药物作用靶点或疗效的指标.寻找对ODC有作用的药物对于治疗其相关疾病是非常有意义的. 相似文献
56.
Niamh M. Kelly Jessica V. Keane Rachel B. Gallimore Debra Bick Rachel M. Tribe 《Maternal & child nutrition》2020,16(2)
There is evidence that caesarean section delivery can impact on neonatal weight loss and weight gain patterns in the first 5 days of life. We conducted an integrative systematic review to examine the association of mode of delivery on early neonatal weight loss. Pubmed, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Excerpta Medica dataBASE, and Medical Literature Analysis and Retrieval System Online were searched for relevant papers published before June 2019. Reference lists from the relevant papers were then backwards and forwards searched. As neonatal weight loss was reported in different formats, a meta‐analysis could not be carried out. Most studies did not distinguish between elective and emergency caesarean sections or instrumental and nonassisted vaginal deliveries. Seven papers were included. All papers except one found that caesarean section was associated with higher weight loss in the early days of life. Two papers presented data from studies on babies followed up to 1 month. One study found that on day 25, babies born by caesarean section had significantly higher weight gain than those born vaginally, while another found that by day 28, babies born vaginally gained more weight per day (11.9 g/kg/day) than those born by caesarean section (10.9 g/kg/day; p = .02). Overall, infants born by caesarean section lost more weight than those born vaginally, but due to the small number of studies included, more are needed to look at this difference and why it may occur. This discrepancy in weight between the two groups may be corrected over time, but future studies will need larger sample sizes and longer follow‐up periods to examine this. 相似文献
57.
58.
目的:分析血管紧张素原基因启动子区A-20C和A-6G单核苷酸多态性与蒙古族人群原发性高血压的相关性。方法:实验于2005-08/2006-01在北京华大实验室完成。选取对象均为生活在内蒙古乌拉特后旗的蒙古族牧民,三代血亲内无其他民族。采用基因测序技术对内蒙古蒙古族人群中107例原发性高血压患者和108例正常对照者进行A-20C和A-6G基因分型,观察高血压组和正常对照组不同基因型的分布和等位基因频率的差异。结果:①两组受试者在性别、年龄及吸烟、饮酒、体质量指数和临床化验检查指标有较好的匹配(P均>0.05)。②两组血管紧张素原基因A-20C位点AA,AC,CC基因型频率比较差异无显著性意义(高血压组分别为0.51,0.29,0.20;正常对照组分别为0.49,0.28,0.23,χ2=0.395,P=0.529)。A,C等位基因频率比较差异无显著性意义(高血压组分别为0.65,0.35;正常对照组分别为0.63,0.37,χ2=0.015,P=0.904)。③两组血管紧张素原基因A-6G位点AA,AG,GG基因型频率比较差异无显著性意义(高血压组分别为0.50,0.33,0.17;正常对照组分别为0.55,0.34,0.11,χ2=1.924,P=0.165)。A,G等位基因频率比较差异无显著性意义(高血压组分别为0.66,0.34;正常对照组分别为0.72,0.28,χ2=1.728,P=0.189)。④高血压组协同存在血管紧张素原基因A-20C基因型CC时,血管紧张素原基因A-6G基因型GG频率稍高于正常对照组,但差异无显著性意义(χ2=2.395,P=0.122,OR=7.52,95%CI0.014~1.250),高血压组G等位基因明显高于正常对照组(分别为0.37,0.22,χ2=4.658,P=0.034),携带该等位基因的蒙古族人群发生原发性高血压的相对危险度升高(OR=2.80,95%CI1.087~7.271)。结论:血管紧张素原基因A-20C和A-6G单核苷酸多态性与蒙古族人群原发性高血压相关,并可能具有协同作用。 相似文献
59.
60.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献